AMENDMENT UNDER 37 C.F.R. § 1.111 Attorney Docket No.: Q92163

Application No.: 10/566,572

## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

## LISTING OF CLAIMS:

 (currently amended): A 4,5-dihydronaphtho[1,2-b]thiophene derivative expressed by the formula:

(wherein  $R^1$  is a  $C_1$  to  $C_{10}$  1-hydroxyalkyl group or a  $C_1$  to  $C_{10}$  acyl group, and  $R^2$  and  $R^3$  separately substitute in the 6-, 7-, 8-, or 9-positions, and are each independently a hydrogen atom, a halogen atom, a  $C_1$  to  $C_{10}$  alkyl group, a hydroxy group, a  $C_1$  to  $C_{10}$  alkoxy group, a  $C_1$  to  $C_5$  alkenyloxy group, a  $C_1$  to  $C_5$  alkenyloxy group, a corresponding group, a ratification of a group expressed by the formula -NR $^4$ R $^5$  (wherein  $R^4$  and  $R^5$  are each independently a hydrogen atom, an acetyl group, a trifluoroacetyl group, a  $C_1$  to  $C_{10}$  alkyl group, or a benzyl group), or  $R^2$  and  $R^3$  are bonded together to form an ethylenedioxy group, provided that when  $R^1$  is an acyl group and  $R^2$  is a hydrogen atom, then  $R^3$  is neither a hydrogen atom nor an acetyl group), or a pharmaceutically acceptable salt thereof.

2. (original): The 4,5-dihydronaphtho[1,2-b]thiophene derivative or  $pharmaceutically acceptable salt thereof according to Claim 1, wherein <math>R^1$  is a 1-hydroxyethyl group, and  $R^2$  and  $R^3$  are each independently a hydrogen atom, a halogen atom, a  $C_1$  to  $C_{10}$  alkyl

AMENDMENT UNDER 37 C.F.R. § 1.111 Attorney Docket No.: Q92163

Application No.: 10/566,572

group, a hydroxy group, a  $C_1$  to  $C_{10}$  alkoxy group, a  $C_1$  to  $C_5$  alkenyloxy group, a  $C_1$  to  $C_5$  alkynyloxy group, a benzyloxy group, a nitro group, an acetyl group, or a group expressed by the formula -NR<sup>4</sup>R<sup>5</sup> (wherein R<sup>4</sup> and R<sup>5</sup> are each independently a hydrogen atom, an acetyl group, a trifluoroacetyl group, a  $C_1$  to  $C_{10}$  alkyl group, or a benzyl group), or  $R^2$  and  $R^3$  are bonded together to form an ethylenedioxy group.

- 3. (original): The 4,5-dihydronaphtho[1,2-b]thiophene derivative or pharmaceutically acceptable salt thereof according to Claim 1, wherein  $R^1$  is an acetyl group,  $R^2$  is a halogen atom, a  $C_1$  to  $C_{10}$  alkyl group, a hydroxy group, a  $C_1$  to  $C_{10}$  alkoxy group, a  $C_1$  to  $C_5$  alkenyloxy group, a  $C_1$  to  $C_5$  alkenyloxy group, a  $C_1$  to  $C_5$  alkenyloxy group, a trifluoroacetyl group, a  $C_1$  to  $C_1$ 0 alkyl group, or a benzyl group), and  $C_1$ 0 a acetyl group, a trifluoroacetyl group, a  $C_1$ 1 to  $C_1$ 0 alkyl group, or a benzyl group), and  $C_1$ 1 is a hydrogen atom, a halogen atom, a  $C_1$ 1 to  $C_1$ 0 alkyl group, a  $C_1$ 1 to  $C_5$ 1 alkynyl group, a hydroxy group, a  $C_1$ 1 to  $C_1$ 0 alkoxy group, a benzyloxy group, a nitro group, or a group expressed by the formula - $C_1$ 1 to  $C_1$ 2 alkoxy group, a benzyloxy group, a hydroxy group, a  $C_1$ 1 to  $C_1$ 2 alkyl group, a  $C_1$ 3 and  $C_1$ 3 are each independently a hydrogen atom, an acetyl group, a trifluoroacetyl group, a  $C_1$ 1 to  $C_1$ 2 alkyl group, or a benzyl group), or  $C_1$ 2 and  $C_2$ 3 are bonded together to form an ethylenedioxy group.
- 4. (original): The 4,5-dihydronaphtho[1,2-b]thiophene derivative or pharmaceutically acceptable salt thereof according to Claim 2, wherein R<sup>1</sup> is a 1-hydroxyethyl group and R<sup>2</sup> and R<sup>3</sup> are each independently a C<sub>1</sub> to C<sub>10</sub> alkyl group or a C<sub>1</sub> to C<sub>10</sub> alkoxy group.

AMENDMENT UNDER 37 C.F.R. § 1.111 Attorney Docket No.: Q92163

Application No.: 10/566,572

5. (original): The 4,5-dihydronaphtho[1,2-b]thiophene derivative or pharmaceutically acceptable salt thereof according to Claim 3, wherein  $R^1$  is an acetyl group and  $R^2$  and  $R^3$  are each independently a  $C_1$  to  $C_{10}$  alkyl group or a  $C_1$  to  $C_{10}$  alkoxy group.

- (original): A pharmaceutical composition comprising the
  4,5-dihydronaphtho[1,2-b]thiophene derivative or pharmaceutically acceptable salt thereof according to any one of Claims 1 to 5.
- (original): A hypotriglyceridemic agent whose active ingredient is the 4,5dihydronaphtho[1,2-b]thiophene derivative or pharmaceutically acceptable salt thereof according to any one of Claims 1 to 5.
- 8. (original): A hypoglycemic agent whose active ingredient is the 4,5-dihydronaphtho[1,2-b]thiophene derivative or pharmaceutically acceptable salt thereof according to any one of Claims 1 to 5.
- 9. (currently amended): An agent for preventing or-treating diabetes, hyperlipidemia, fatty liver, obesity, impaired glucose tolerance, diabetes complications, metabolic syndrome, and syndrome X, whose active ingredient is the 4,5-dihydronaphtho[1,2-b]thiophene derivative or pharmaceutically acceptable salt thereof according to any one of Claims 1 to 5.